{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:43:56Z","timestamp":1761101036511},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,6,14]],"date-time":"2010-06-14T00:00:00Z","timestamp":1276473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,6,14]],"date-time":"2010-06-14T00:00:00Z","timestamp":1276473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1038\/bmt.2010.145","type":"journal-article","created":{"date-parts":[[2010,6,14]],"date-time":"2010-06-14T12:08:50Z","timestamp":1276517330000},"page":"545-551","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prognostic factors in allo-SCT of elderly patients with AML"],"prefix":"10.1038","volume":"46","author":[{"given":"J","family":"Krauter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Dammann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Zucknick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Mischak-Weissinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hertenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,14]]},"reference":[{"key":"BFbmt2010145_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","volume":"341","author":"B L\u00f6wenberg","year":"1999","unstructured":"L\u00f6wenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051\u20131062.","journal-title":"N Engl J Med"},{"key":"BFbmt2010145_CR2","first-page":"296","volume":"89","author":"A Pulsoni","year":"2004","unstructured":"Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M et al. Survival of elderly patients with acute myeloid leukemia. Haematologica 2004; 89: 296\u2013302.","journal-title":"Haematologica"},{"key":"BFbmt2010145_CR3","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481\u20133485.","journal-title":"Blood"},{"key":"BFbmt2010145_CR4","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","volume":"108","author":"S Frohling","year":"2006","unstructured":"Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006; 108: 3280\u20133288.","journal-title":"Blood"},{"key":"BFbmt2010145_CR5","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","volume":"22","author":"RF Schlenk","year":"2004","unstructured":"Schlenk RF, Benner A, Krauter J, B\u00fcchner T, Sauerland C, Ehninger G et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22: 3741\u20133750.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010145_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","volume":"27","author":"T Buchner","year":"2009","unstructured":"Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61\u201369.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010145_CR7","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.2005.05.694","volume":"23","author":"H Wallen","year":"2005","unstructured":"Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23: 3439\u20133446.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010145_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1399-0012.2005.00453.x","volume":"20","author":"M Ditschkowski","year":"2006","unstructured":"Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW . Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients. Clin Transplant 2006; 20: 127\u2013131.","journal-title":"Clin Transplant"},{"key":"BFbmt2010145_CR9","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"M Aoudjhane","year":"2005","unstructured":"Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304\u20132312.","journal-title":"Leukemia"},{"key":"BFbmt2010145_CR10","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","volume":"27","author":"O Ringden","year":"2009","unstructured":"Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570\u20134577.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010145_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.beha.2008.06.005","volume":"21","author":"FR Appelbaum","year":"2008","unstructured":"Appelbaum FR . What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)? Best Pract Res Clin Haematol 2008; 21: 667\u2013675.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFbmt2010145_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00277-001-0384-9","volume":"80","author":"HD Ottinger","year":"2001","unstructured":"Ottinger HD, Muller CR, Goldmann SF, Albert E, Arnold R, Beelen DW et al. Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells. Ann Hematol 2001; 80: 706\u2013714.","journal-title":"Ann Hematol"},{"key":"BFbmt2010145_CR13","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642\u20134649.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010145_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/sim.4780050306","volume":"5","author":"EL Korn","year":"1986","unstructured":"Korn EL . Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986; 5: 255\u2013260.","journal-title":"Stat Med"},{"key":"BFbmt2010145_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Ass 1999; 94: 496\u2013509.","journal-title":"J Am Stat Ass"},{"key":"BFbmt2010145_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ajh.20989","volume":"82","author":"CM Flynn","year":"2007","unstructured":"Flynn CM, Hirsch B, Defor T, Barker JN, Miller JS, Wagner JE et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007; 82: 867\u2013872.","journal-title":"Am J Hematol"},{"key":"BFbmt2010145_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","volume":"108","author":"R Martino","year":"2006","unstructured":"Martino R, Iacobelli S, Brand R, Jansen T, van BA, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836\u2013846.","journal-title":"Blood"},{"key":"BFbmt2010145_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/sj.leu.2403591","volume":"19","author":"A Shimoni","year":"2005","unstructured":"Shimoni A, Kroger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005; 19: 7\u201312.","journal-title":"Leukemia"},{"key":"BFbmt2010145_CR19","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.","journal-title":"Blood"},{"key":"BFbmt2010145_CR20","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","volume":"110","author":"ML Sorror","year":"2007","unstructured":"Sorror ML, Giralt S, Sandmaier BM, de LM, Shahjahan M, Maloney DG et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110: 4606\u20134613.","journal-title":"Blood"},{"key":"BFbmt2010145_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/sj.bmt.1705747","volume":"40","author":"TL Kiss","year":"2007","unstructured":"Kiss TL, Sabry W, Lazarus HM, Lipton JH . Blood and marrow transplantation in elderly acute myeloid leukaemia patients\u2014older certainly is not better. Bone Marrow Transplant 2007; 40: 405\u2013416.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010145_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/sj.bmt.1704062","volume":"31","author":"HG Sayer","year":"2003","unstructured":"Sayer HG, Kroger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31: 1089\u20131095.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010145_CR23","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1200\/JCO.2007.15.5184","volume":"26","author":"J Schetelig","year":"2008","unstructured":"Schetelig J, Bornhauser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26: 5183\u20135191.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010145_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/j.1365-2362.2008.02041.x","volume":"38","author":"A Boehm","year":"2008","unstructured":"Boehm A, Sperr WR, Leitner G, Worel N, Oehler L, Jaeger E et al. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest 2008; 38: 945\u2013952.","journal-title":"Eur J Clin Invest"},{"key":"BFbmt2010145_CR25","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","volume":"25","author":"ML Sorror","year":"2007","unstructured":"Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246\u20134254.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010145_CR26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092\u20131099.","journal-title":"Blood"},{"key":"BFbmt2010145_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood-2007-08-104745","volume":"112","author":"R Marks","year":"2008","unstructured":"Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008; 112: 415\u2013425.","journal-title":"Blood"},{"key":"BFbmt2010145_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855\u2013864.","journal-title":"Lancet Oncol"},{"key":"BFbmt2010145_CR29","first-page":"S281","volume":"43","author":"S Buchholz","year":"2009","unstructured":"Buchholz S, Krauter J, Dammann E, Beutel G, Stadler M, Eder M et al. Cytoreduction with clofarabine\/Ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute leukemia. Bone Marrow Transplant 2009; 43: S281\u2013S282.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010145_CR30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.2005.03.1765","volume":"24","author":"U Hegenbart","year":"2006","unstructured":"Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444\u2013453.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2010145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010145","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:21:49Z","timestamp":1648041709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2010145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,14]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["BFbmt2010145"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2010.145","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,14]]},"assertion":[{"value":"8 January 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}